Evolving subclonal mutations can resist and escape treatment
"We have a profound gap in knowledge between the interaction of a person, their cancer, and their therapy and how that impacts response. We need better insight."
- Jerry Radich, MD
Break Out of the Limitations of Bulk.
The average read-out from conventional bulk sequencing misses the underlying genetic diversity across cell populations. To improve patient stratification, therapy selection, and disease monitoring we need insights into mutation co-occurrence within every single cell.
The industry’s first scalable, customizable, single-cell DNA analysis platform.
The Mission Bio Tapestri Platform was developed to help advance precision medicine by enabling the accelerated and accessible detection of genomic variability within and across cell populations. Leveraging proprietary droplet microfluidics, the platform unlocks access to DNA at the single-cell level with a novel two-step protease workflow. This methodology provides flexibility for additional applications and customization capability.
How the Tapestri Platform Works
High Sensitivity to Reveal True Heterogeneity
The Tapestri Platform revolutionizes the capability to directly assess the clonal architecture of a sample with detection of mutation co-occurrence patterns. Rather than inferring variants that co-occur within a subclone from comparable bulk variant allele frequencies, single-cell resolution uncovers the true distribution of genotypes and their segregation patterns across subclones.
- Detect rare subclones down to 0.1%
- Resolve clonal architecture
- Identify mutation co-occurrence
- Targeted and accurate SNVs and indel variant calling
- Single-cell DNA throughput up to 10,000 cells
- Simple workflow
- User-friendly bioinformatics software
- Customizable content